Study of Inhaled Corticosteroids with Bronchodilators and PD-L1 Inhibitor Plus Chemotherapy in Advanced Lung Squamous Cell Carcinoma with COPD

What this Trial Is About

Researchers are evaluating the effectiveness and safety of combining inhaled corticosteroids with bronchodilators and a programmed death-ligand 1 (PD-L1) inhibitor plus platinum-based chemotherapy in patients who have advanced lung squamous cell carcinoma alongside chronic obstructive pulmonary disease (COPD). This study focuses on patients with stage IIIB-IV squamous non-small cell lung cancer who also have stable moderate to severe COPD, aiming to improve treatment outcomes in this complex condition. All patients receive a combination of suglizumab, paclitaxel (albumin-bound), and carboplatin chemotherapy over four cycles, with suglizumab continued every three weeks afterward. Sixty patients are randomly assigned to two groups: one group receives a long-acting beta-2 agonist plus a long-acting anticholinergic inhaler twice daily, and the other group receives an inhaled corticosteroid combined with both bronchodilators twice daily. These treatments are delivered via inhalation to manage COPD alongside cancer therapy. During the study, participants are closely monitored for the time and severity of the first acute worsening of COPD for up to two years. Researchers collect clinical evaluations and treatment records, ensuring patients meet specific health criteria before starting. Safety assessments include monitoring liver and kidney function, respiratory status, and adverse effects related to medications. The study involves careful tracking of treatment adherence and comprehensive follow-up to evaluate long-term outcomes and safety.

To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)